Order Article Reprints

Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, et al. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics. 2020; 9(4):145. https://doi.org/10.3390/antibiotics9040145

Kaji, Kosuke, Soichiro Saikawa, Hiroaki Takaya, Yukihisa Fujinaga, Masanori Furukawa, Koh Kitagawa, Takahiro Ozutsumi, Daisuke Kaya, Yuki Tsuji, Yasuhiko Sawada, and et al. 2020. "Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients" Antibiotics 9, no. 4: 145. https://doi.org/10.3390/antibiotics9040145

Kaji, K., Saikawa, S., Takaya, H., Fujinaga, Y., Furukawa, M., Kitagawa, K., Ozutsumi, T., Kaya, D., Tsuji, Y., Sawada, Y., Kawaratani, H., Moriya, K., Namisaki, T., Akahane, T., Mitoro, A., & Yoshiji, H. (2020). Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics, 9(4), 145. https://doi.org/10.3390/antibiotics9040145